StockData
Palvella Therapeutics, Inc. logo

Palvella Therapeutics, Inc. (PVLA) stock

PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$146.58+2.23 (+1.54%)

Close on Nov 18, 2026Market cap $2.11BP/E –Yield –

Palvella Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Palvella Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$36.51M. For fiscal 2025 it was -$25.01M. The highest annual figure on record is $49.75M in fiscal 2017.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$25.01M–
FY2024Dec 31, 2024-$10.84M–
FY2023Dec 31, 2023-$13.70M–
FY2022Dec 31, 2022-$59.93M–
FY2021Dec 31, 2021-$7.66M–
FY2020Dec 31, 2020-$45.90M–
FY2019Dec 31, 2019-$52.47M–
FY2018Dec 31, 2018-$1.07M-102.1%
FY2017Dec 31, 2017$49.75M–
FY2016Dec 31, 2016-$14.39M–
FY2015Dec 31, 2015-$12.71M–
FY2014Dec 31, 2014-$5.07M–
FY2013Dec 31, 2013-$3.08M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$12.85M–
Q1 FY2026Mar 31, 2026-$10.86M–
Q4 FY2025Dec 31, 2025-$4.93M–
Q3 FY2025Sep 30, 2025-$7.88M–
Q2 FY2025Jun 30, 2025-$5.43M–
Q1 FY2025Mar 31, 2025-$6.77M–
Q4 FY2024Dec 31, 2024-$5.39M-126.4%
Q3 FY2024Sep 30, 2024-$2.74M–
Q2 FY2024Jun 30, 2024-$1.60M–
Q1 FY2024Mar 31, 2024-$1.10M–
Q4 FY2023Dec 31, 2023$20.45M–
Q3 FY2023Sep 30, 2023-$9.72M–
Q2 FY2023Jun 30, 2023-$13.43M–
Q1 FY2023Mar 31, 2023-$11.00M–
Q4 FY2022Dec 31, 2022-$12.93M–
Q3 FY2022Sep 30, 2022-$8.78M–
Q2 FY2022Jun 30, 2022-$15.58M-152.1%
Q1 FY2022Mar 31, 2022-$22.64M–
Q4 FY2021Dec 31, 2021-$10.94M–
Q3 FY2021Sep 30, 2021-$14.48M–
Q2 FY2021Jun 30, 2021$29.91M–
Q1 FY2021Mar 31, 2021-$12.14M–
Q4 FY2020Dec 31, 2020-$13.42M–
Q3 FY2020Sep 30, 2020-$7.57M–
Q2 FY2020Jun 30, 2020-$9.78M–
Q1 FY2020Mar 31, 2020-$15.13M–
Q4 FY2019Dec 31, 2019-$13.97M–
Q3 FY2019Sep 30, 2019-$12.65M–
Q2 FY2019Jun 30, 2019-$10.73M–
Q1 FY2019Mar 31, 2019-$15.11M-148.2%
Q4 FY2018Dec 31, 2018-$9.06M–
Q3 FY2018Sep 30, 2018-$14.36M-140.8%
Q2 FY2018Jun 30, 2018-$8.99M–
Q1 FY2018Mar 31, 2018$31.34M+21.6%
Q4 FY2017Dec 31, 2017-$4.69M–
Q3 FY2017Sep 30, 2017$35.20M–
Q2 FY2017Jun 30, 2017-$6.52M–
Q1 FY2017Mar 31, 2017$25.77M–
Q4 FY2016Dec 31, 2016-$6.73M–
Q3 FY2016Sep 30, 2016-$3.58M–

More Palvella Therapeutics figures

See a number that looks wrong?